EMA Authorised: Cholib (fenofibrate;simvastatin) — Viatris Healthcare Limited

View source ↗

Summary

The EMA has authorised Cholib, a fixed-dose combination of fenofibrate and simvastatin, for dyslipidemias.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Dyslipidemias

Drugs mentioned

• Cholib (fenofibrate; simvastatin)

Snippet

Status: Authorised. Therapeutic area: Dyslipidemias. MAH: Viatris Healthcare Limited. Decision date: 15/12/2025